7 studies found for:    "Conjunctival melanoma"
Show Display Options
Rank Status Study
1 Recruiting Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma
Conditions: Eye Disease;   Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping and Biopsy
2 Terminated
Has Results
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: sunitinib malate
3 Unknown  Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
4 Completed Vaccine Therapy in Treating Patients With Advanced Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Procedure: biopsy
5 Completed Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: MART-1:27-35 peptide vaccine;   Biological: gp100:209-217(210M) peptide vaccine;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tyrosinase peptide;   Drug: agatolimod sodium;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique
6 Completed Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Condition: Cancer
Interventions: Drug: isolated perfusion;   Drug: melphalan
7 Completed Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Condition: Cancer
Interventions: Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 );   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2);   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3);   Procedure: Blood sampling

Indicates status has not been verified in more than two years